TITLE

Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in persons at risk: COMMENTARY

AUTHOR(S)
Shaw, James E.
PUB. DATE
November 2003
SOURCE
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p72
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A series of animal experiments as well as epidemiologic studies dating back to the early 1980s have supported the protective effects of non-steroidal anti-inflammatory drugs against the development of colorectal adenomas. Over time, these studies have been consistent and positive, and now, with the studies by researchers J.A. Baron and colleagues and R.S. Sandler and colleagues, 2 well-designed, randomized, placebo-controlled trials can be added to this body of evidence. In the study by Baron and colleagues, 2 doses of aspirin, 81 mg and 325 mg daily, were compared with placebo. A modest 19% reduction in the relative risk for any adenoma was found in patients who received aspirin, 81 mg/d, but no significant protection was found in those who received aspirin, 325 mg/d, when compared with placebo. The side effects from regular use of aspirin were similar to placebo in the study by Sandier and colleagues.
ACCESSION #
11533511

 

Related Articles

  • Aspirin prevented new colorectal adenomas in patients with previous colorectal cancer.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p73 

    This article discusses whether aspirin is effective for preventing the occurrence of new colorectal adenomas in patients with previous colorectal cancer. 635 patients who were 30 to 80 years of age and previously had curative resection of early-stage colon or rectal cancer and colonoscopy to the...

  • Chemoprophylaxis with aspirin (81 mg daily) reduced the incidence of colorectal adenomas in persons at risk.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p72 

    This article discusses whether chemoprophylaxis with aspirin is more effective than placebo for reducing the incidence of colorectal adenomas in persons at risk of histologically documented adenomas. 1121 patients, who were histologically confirmed that their colorectal adenoma was removed in...

  • Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in rats. Barnes, C J; Lee, M // British Journal of Cancer;4/1/99, Vol. 79 Issue 11/12, p1646 

    In order to establish an optimal timing and duration of aspirin treatment in the chemoprevention of 1,2-dimethylhydrazine (DMH)-induced colon cancer in rats, colon tumours were induced using an established protocol and aspirin was given in the diet at 500 p.p.m. during various stages of colon...

  • Celecoxib for colorectal adenomas increased CV events. Solomon, S. D.; Mcmurray, J. J.; Pfeffer, M. A. // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p107 

    The article presents a study analyzing that celecoxib for colorectal adenomas increases cardiovascular (CV) events. Compared with placebo, 800 mg/day of celecoxib increased CV death or non-fatal MI and CV death, non-fatal MI, or stroke, regardless of whether patients took low doses of aspirin....

  • New Data on Aspirin and Colorectal Cancer Brings Calls for New Guidelines, More Research. McNeil, Caroline // JNCI: Journal of the National Cancer Institute;Feb2012, Vol. 104 Issue 3, p172 

    The article highlights three studies which showed aspirin's benefits after long-term follow-up. The first study found that daily aspirin statistically reduced incidence and mortality from colorectal cancer. The second study led by Peter Rothwell, on the other hand, showed that aspirin reduced...

  • Aspirin use and colorectal cancer risk. Nicklin, David; Russell, John J. // Patient Care;Nov2005, Vol. 39 Issue 11, p67 

    The article discusses research being done on the effect of aspirin administration on the risk of colon cancer in women. It references a study by A. T. Chan et al published in the 2005 issue of the "Journal of American Medical Association. The study found that regular use of aspirin reduces the...

  • Aspirin in the Prevention of Colorectal Cancer. Garewal, Harinder S. // Annals of Internal Medicine;8/15/94, Vol. 121 Issue 4, p303 

    Editorial. Discusses the approaches to decreasing the morbidity and mortality from colorectal cancer. Information on chemoprevention; Side effects of nonsteroidal anti-inflammatory drugs; Appeal of aspirin as a viable option for widespread use.

  • Daily aspirin reduced incidence of colorectal cancer.  // Australian Journal of Pharmacy;Apr2012, Vol. 93 Issue 1103, p90 

    The article focuses on a CAPP2 trial conducted in order to evaluate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, a major form of hereditary colorectal cancer. The study involves the random assignment of the carriers of Lynch syndrome in a two-by-two...

  • Insights into chemoprevention of colorectal cancer from the Nurses Health Study.  // Gut;Jan2006, Vol. 55 Issue 1, p114 

    The article provides an insight into chemoprevention of colorectal cancer from the Nurses Health Study. Non-steroidal anti-inflammatory drugs have been associated with a reduced risk of colorectal cancer and randomized controlled trials have suggested that aspirin reduces the recurrence of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics